On the basis of our results that TPL2 mediates oncogenic JNK signaling by LMP1 and cell survival of EBV-transformed cells, TPL2 should be considered as an attractive target for new drugs or the repurposing of existing inhibitors against EBV-induced malignancies such as PTLD in the future. Here, PDLIM7 is linked to post-transplant lymphoproliferative disease.